-
Security Type
-
Convertible Note
-
Min Investment
-
$100
-
Offering Date
-
February 09, 2021
-
Expected Close Date
-
April 30, 2021
-
Target Raise
-
$250.00K-$1.07M
-
Deal Notes
-
Price Per Share: $1.00
Company Description
PROTXX innovations in wearable sensors and machine learning transform the lives of tens of millions of people living with complex neurophysiological conditions.
Key Deal Facts
Invented 1 minute non-invasive test that identifies and quantifies neuromotor and neurosensory impairments
PAAS model enhances management and treatment of concussions, stroke, Parkinson's, multiple sclerosis
Our solution is commercially available with over 20 customers and pilots in U.S., Canada, U.K., Japan
We reduce time, travel, and costs for patients through remote patient monitoring
Institute of Health Economics set value-based pricing of $5,000 per patient per month for PROTXX
Partnered with machine learning and neurophysiology leaders to develop predictive diagnostics
Use of Proceeds
$250,000
- 34% towards product development, 16.5% towards sales & marketing, 21% towards pilot deployments, 14% towards intellectual property and regulatory filings, 8% towards G&A, 6.5% towards WeFunder fees
$1,070,000
- 40% towards product development, 20.5% towards sales & marketing, 14% towards pilot deployments, 10% towards intellectual property and regulatory filings, 9% towards G&A, 6.5% towards WeFunder fees
Management Team / Advisory Board Bios
John Ralston, CEO and Founder
2016 “Pioneer in Healthcare Technology Innovations Award” CEO, Sales & Marketing, R&D at 8 previous Silicon Valley companies (2 IPOs, 8 M&A exits) MIT BSc, Cornell PhD, MIT Sloan MBA/MOT
James Walker, Chief Financial Officer
Has led 4 previous Silicon Valley companies thru IPOs
Joshua Roper, Vice President, Operations
GM, Product Executive, and Technology Leader experienced in Software, Hardware, Networking, Security, and IoT with more than 27M networked devices deployed and well over $2B in revenue